<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959918</url>
  </required_header>
  <id_info>
    <org_study_id>SEL-212/201</org_study_id>
    <nct_id>NCT02959918</nct_id>
  </id_info>
  <brief_title>Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout &amp; Elevated Blood Uric Acid</brief_title>
  <official_title>An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selecta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Selecta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label multicenter study to evaluate the safety and tolerability of multiple
      doses(3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase( SEL-037) and
      SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase
      (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and
      hyperuricemia. Additional subjects will be treated with multiple doses( 5 monthly IV
      infusions) of pegsiticase (SEL-037) alone.

      Subjects will be monitored for safety endpoints through the 5th treatment cycle plus 30 days
      .Pharmacokinetic samples will drawn a pre-determined time points in addition to weekly serum
      uric acid levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label multicenter study to evaluate the safety and tolerability of multiple
      doses(3 monthly IV infusions) of SEL-212( a combination of pegsiticase( SEL-037) and
      SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase
      (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and
      hyperuricemia. Additional subjects will be treated with multiple doses( 5 monthly IV
      infusions) of pegsiticase (SEL-037) alone.

      Uricase is an enzyme that converts uric acid to the readily soluble allantoin that is then
      excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs) from
      forming. All subjects will be monitored for safety and tolerability to drug throughout the
      study on a weekly schedule. Pharmacokinetic and pharmacodynamic parameters will at specific
      timepoints to monitor for continued efficacy. Pharmacodynamic parameters measured include
      uric acid levels and levels of ADAs.

      The study duration per enrolled subject will be approximately 6 months including a 1 month
      screening period followed by 5 treatment cycles and an end of treatment visit which will
      occur 30 days after the last IV infusion .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple intravenous infusions of SEL-212 as assessed by the frequency of drug related adverse events, graded by severity</measure>
    <time_frame>Five monthly infusions</time_frame>
    <description>To determine the safety and tolerability of 3 monthly infusions of SEL-212 followed by 2 monthly infusions of SEL-037 (pegsiticase) as assessed by frequency of drug related adverse events, graded by severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of SEL-037 (pegsiticase) after multiple monthly IV infusions with or without SEL-110</measure>
    <time_frame>5 months</time_frame>
    <description>Measurement of the pharmacokinetics of SEL-037, with or without SEL-110, for 30 days after multiple monthly IV infusions by area under the blood concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) (ability to reduce circulating uric acid) of SEL-037 after multiple monthly IV infusions with or without SEL-110</measure>
    <time_frame>5 months</time_frame>
    <description>Measurement of the pharmacodynamics (ability to reduce circulating uric acid) of SEL-037 after multiple monthly infusions with or without SEL-110 by measurement of blood uric acid levels for 30 days post infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SEL-037 after multiple monthly IV infusions with our without SEL-110</measure>
    <time_frame>5 months</time_frame>
    <description>Immunogenicity of SEL-037 after multiple monthly IV infusions with or without SEL-110 by measurement of anti-drug antibody levels over 30 days post each infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics (PK) of rapamycin after multiple IV infusions of SEL-110 with multiple IV infusions of SEL-037.</measure>
    <time_frame>5 months</time_frame>
    <description>To determine the pharmacokinetics of rapamycin after multiple I V infusions of SEl-212 by area under the blood concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The effect on uric acid deposits and/or total body uric acid deposited as measured by Dual Energy Computed Tomography scan of multiple doses of SEL-037 alone or multiple doses of SEL-212 plus additional doses of SEL-037.</measure>
    <time_frame>Baseline and 5 months</time_frame>
    <description>To measure the change in uric acid deposits in specified joints from beginning to end of treatment</description>
  </other_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Gout Chronic</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>SEL-037 Pegsiticase LD(low dose) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-037 Pegsiticase HD(high dose) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (2b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL-212</intervention_name>
    <description>SEL-212</description>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (1a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (1b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (2a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (2b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL-037</intervention_name>
    <description>SEL-037, biologic</description>
    <arm_group_label>SEL-037 Pegsiticase LD(low dose) alone</arm_group_label>
    <arm_group_label>SEL-037 Pegsiticase HD(high dose) alone</arm_group_label>
    <other_name>pegsiticase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SVP-rapamycin (SEL-110)</intervention_name>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (1a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (1b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (2a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (2b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6b)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (age 21-75 inclusive) men and women of non child bearing potential with
             established or symptomatic gout which is defined as having at least ONE of any of the
             3 following factors:

               1. ≥ 1 tophus

               2. 1 gout flare within the last 6 months

               3. Chronic gouty arthropathy

          2. Screening serum uric acid of &gt;6ng/dL

          3. On a gout flare prophylactic regimen for 7 days prior to first dose

          4. Willing to provide written informed consent prior to first study procedure is
             performed.

          5. Understands and is willing and able to comply with study requirements, including the
             schedule of follow-up visits.

        Exclusion Criteria:

          1. History of anaphylaxis or severe allergic reaction.

          2. History of an allergy to pegylated products.

          3. Women of child bearing potential, Defined as:

               -  &lt;6 weeks after surgical bilateral salpingooperhectony with or without
                  hysterectomy

               -  Pre or perimenopausal ( &lt; less than 24 months of natural amenorrhea)

          4. Initiation or change in dose of hormone-replacement therapy for menopausal women less
             than 1 month prior to the Screening Visit or during the Screening Phase would be
             exclusionary. If after being on a stable dose of hormone-replacement therapy for one
             month the patient may be considered for the study if she continues to meet all other
             inclusion and exclusion criteria

          5. Uncontrolled diabetes with baseline HbA1c ≥8%;

          6. Glucose-6-phosphate dehydrogenase deficiency;

          7. Uncontrolled hypertension

          8. Ongoing treatment for arrhythmia, including placement of an implantable defibrillator;

          9. History of coronary artery disease, including myocardial infarction;

         10. Congestive heart failure, New York Heart Association Class III or IV;

         11. ECG with evidence of prior myocardial infarction, clinically significant arrhythmia,
             or other abnormalities that, in the opinion of the investigator, are consistent with
             significant underlying cardiac disease;

         12. History of hematological or autoimmune disorders, is immunosuppressed or
             immunocompromised;

         13. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek,
             Fasturtec), pegloticase (Krystexxa®), pegsiticase (SEL-037)

         14. History of malignancy within the last 5 years other than basal skin cancer;

         15. Subjects who, in the opinion of the investigator, present with a condition that would
             compromise their safety or that would make study completion unlikely.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Earl E Sands, MD</last_name>
    <phone>617-923-1400</phone>
    <phone_ext>8122</phone_ext>
    <email>ssands@selectabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lloyd Johnston, PhD</last_name>
    <phone>617-932-1400</phone>
    <phone_ext>8105</phone_ext>
    <email>ljohnston@selectabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri West Research Associates LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Research Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants LLC</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>L-MARC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

